loading...| Preferred Name |
Treatment of PSA-only recurrence after treatment with curative intent |
|
| Synonyms |
|
|
| Definitions |
"Primary curative procedures such as RP, and RT are well-established therapeutic options in the management of localised PCa. Despite technical improvements, there is still a significant risk of cancer recurrence after therapy. Between 27% and 53% of all patients undergoing RP or RT develop PSA-recurrence. While a rising PSA level universally antedates metastatic progression and prostate-cancer-specific mortality (PCSM), physicians must inform the patient that the natural history of PSA-only recurrence may be prolonged and that a PSA rise is not a surrogate for these survival endpoints. Physicians treating patients with PSA-only recurrence face a difficult set of decisions in attempting to delay the onset of metastatic disease and death while avoiding over-treating patients whose disease may never affect their OS or QoL. It has to be emphasised that the treatment recommendations for these patients should be given after discussion with a multidisciplinary team." |
|
| ID |
http://www.semanticweb.org/ontologies/2018/1/ProstateCancer.owl#Treatment_of_PSA-only_recurrence_after_treatment_with_curative_intent |
|
| ChineseLabel |
根治性目的治疗后仅限PSA复发的治疗 |
|
| definition |
"Primary curative procedures such as RP, and RT are well-established therapeutic options in the management of localised PCa. Despite technical improvements, there is still a significant risk of cancer recurrence after therapy. Between 27% and 53% of all patients undergoing RP or RT develop PSA-recurrence. While a rising PSA level universally antedates metastatic progression and prostate-cancer-specific mortality (PCSM), physicians must inform the patient that the natural history of PSA-only recurrence may be prolonged and that a PSA rise is not a surrogate for these survival endpoints. Physicians treating patients with PSA-only recurrence face a difficult set of decisions in attempting to delay the onset of metastatic disease and death while avoiding over-treating patients whose disease may never affect their OS or QoL. It has to be emphasised that the treatment recommendations for these patients should be given after discussion with a multidisciplinary team." |
|
| label |
Treatment of PSA-only recurrence after treatment with curative intent |
|
| prefixIRI |
ProstateCancer:Treatment_of_PSA-only_recurrence_after_treatment_with_curative_intent |
|
| prefLabel |
Treatment of PSA-only recurrence after treatment with curative intent |
|
| subClassOf |
http://www.semanticweb.org/ontologies/2018/1/ProstateCancer.owl#Other_treatment |